Dantrolene in the Treatment of Refractory Hyperthermic Conditions in Critical Care: A Multicenter Retrospective Study

Shonali C. Pawar; Henry Rosenberg; Robert Adamson; Jennifer A. LaRosa; Ronald Chamberlain

doi:10.4236/ojanes.2015.54013

Home > Journals > Medicine & Healthcare > OJAnes

Open Journal of Anesthesiology > Vol.5 No.4, April 2015

Dantrolene in the Treatment of Refractory Hyperthermic Conditions in Critical Care: A Multicenter Retrospective Study ()

Shonali C. Pawar¹, Henry Rosenberg^1,2*, Robert Adamson³, Jennifer A. LaRosa⁴, Ronald Chamberlain¹

¹Department of Surgery, Saint Barnabas Medical Center, Livingston, USA.
²Department of Medical Education and Clinical Research, Saint Barnabas Medical Center, Livingston, USA.
³Corporate Pharmaceutical Sciences, Barnabas Health Care, Livingston, NJ, USA.
⁴Department of Pulmonary and Critical Care Medicine, Newark Beth Israel Medical Center, Newark, NJ, USA.

DOI: 10.4236/ojanes.2015.54013 PDF HTML XML 2,898 Downloads 3,636 Views

Abstract

Purpose: To examine the use of intravenous dantrolene in hospitalized patients. Materials and Methods: Medical Records of patients treated with intravenous dantrolene between 2007 and 2012 at 6 teaching hospitals were reviewed. Temperature, muscle rigidity, creatine kinase levels, and mortality were assessed in association with dantrolene use. Results: Twenty-five patients received intravenous dantrolene, 9 patients with neuroleptic malignant syndrome (NMS), 8 with hyperthermia due to sepsis, 4 with NMS and sepsis, 2 for malignant hyperthermia (MH), and 2 with hypermetabolic syndrome associated with juvenile diabetic ketoacidosis. Dantrolene was administered as a bolus of 1 - 3 mg/kg. Core temperature decreased after dantrolene administration in all groups but significant only for MH, NMS cases (Pre 102.3 ± 0.9°F vs. Post 99.5 ± 0.9°F; p < 0.001), in Sepsis cases (Pre 104.3 ± 1.5°F vs. Post 100.6 ± 1.0°F; p < 0.001). Mean rigidity scores decreased in all groups but significant only for NMS cases, and mean CK did not change significantly in any group. Conclusion: Dantrolene was associated with reductions in temperature and rigidity in hyperthermia of diverse origins in patients admitted to Intensive care settings.

Keywords

Dantrolene, Malignant Hyperthermia, Neuroleptic Malignant Syndrome, Sepsis

Share and Cite:

Pawar, S. , Rosenberg, H. , Adamson, R. , LaRosa, J. and Chamberlain, R. (2015) Dantrolene in the Treatment of Refractory Hyperthermic Conditions in Critical Care: A Multicenter Retrospective Study. Open Journal of Anesthesiology, 5, 63-71. doi: 10.4236/ojanes.2015.54013.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Gillman, P.K. (2010) Neuroleptic Malignant Syndrome: Mechanisms, Interactions, and Causality. Movement Disorders, 25, 1780-1790. http://dx.doi.org/10.1002/mds.23220
[2]	Wappler, F. (2001) Malignant Hyperthermia. European Journal of Anaesthesiology, 18, 632-652. http://dx.doi.org/10.1046/j.1365-2346.2001.00888.x
[3]	Musselman, M.E. and Saely, S. (2013) Diagnosis and Treatment of Drug-Induced Hyperthermia. American Journal of Health-System Pharmacy, 70, 34-42. http://dx.doi.org/10.2146/ajhp110543
[4]	Eyer, F. and Zilker, T. (2007) Bench to Bedside Review: Mechanisms and Management of Hyperthermia Due to Toxicity. Critical Care, 11, 236. http://dx.doi.org/10.1186/cc6177
[5]	McAllen, K.J. and Schwartz, D.R. (2010) Adverse Drug Reactions Resulting in Hyperthermia in the Intensive Care Unit. Critical Care Medicine, 38, 244-252. http://dx.doi.org/10.1097/CCM.0b013e3181dda0d4
[6]	Boyer, E.W. and Shannon, M. (2005) The Serotonin Syndrome. The New England Journal of Medicine, 352, 1112-1120. http://dx.doi.org/10.1056/NEJMra041867
[7]	Lefkowitz, D., Ford, C.S., Rich, C., Biller, J. and McHenry Jr., L.C. (1938) Cerebellar Syndrome Following Neuroleptic Induced Heat Stroke. Journal of Neurology Neurosurgery and Psychiatry, 46, 183-185. http://dx.doi.org/10.1136/jnnp.46.2.183
[8]	Hadad, E., Weinbroum, A.A. and Ben-Abraham, R. (2003) Drug Induced Hyperthermia and Muscle Rigidity: A Practical Approach. European Journal of Emergency Medicine, 10, 149-154. http://dx.doi.org/10.1097/00063110-200306000-00018
[9]	Adnet, P., Levstavel, P. and Krivosic-Horber, R. (2000) Neuroleptic Malignant Syndrome. British Journal of Anaesthesia, 85, 129-135. http://dx.doi.org/10.1093/bja/85.1.129
[10]	Denborough, M.A. (1982) Heat Stroke and Malignant Hyperpyrexia. The Medical Journal of Australia, 1, 204-205.
[11]	Meyers, E.F. and Meyers, R.W. (1982) Thermic Stress Syndrome. JAMA, 247, 2098-2099. http://dx.doi.org/10.1001/jama.1982.03320400018018
[12]	Strawn, J.R., Keck, P.E. and Caroff, S.N. (2007) Neuroleptic Malignant Syndrome. American Journal of Psychiatry, 164, 870-876. http://dx.doi.org/10.1176/ajp.2007.164.6.870
[13]	Grunau, B.E., Wiens, M.O. and Brubacher, J.R. (2010) Dantrolene in the Treatment of MDMA-Related Hyperpyrexia: A Systematic Review. Canadian Journal of Emergency Medicine, 12, 435-442.
[14]	Kurz, A. (2008) Physiology of Thermoregulation. Best Practice & Research Clinical Anaesthesiology, 22, 627-644. http://dx.doi.org/10.1016/j.bpa.2008.06.004
[15]	Krause, T., Gerbershagen, M.U., Fiege, M., Weibhorn, R. and Wappler, F. (2004) Dantrolene—A Review of Its Pharmacology, Therapeutic Use and New Developments. Anaesthesia, 59, 364-373.
[16]	Rosenberg, H., Davis, M., James, D., Pollock, N. and Stowell, K. (2007) Malignant Hyperthermia. Orphanet Journal of Rare Diseases, 2, 21. http://dx.doi.org/10.1186/1750-1172-2-21
[17]	Davis, J.M., Caroff, S.N. and Mann, S.C. (2000) Treatment of Neuroleptic Malignant Syndrome. Psychiatric Annals, 30, 325-331. http://dx.doi.org/10.3928/0048-5713-20000501-10
[18]	Caroff, S.N. (2003) Neuroleptic Malignant Syndrome. In: Man, S.C., Caroff, S.N., Keck Jr., P.E. and Lazarus, A., Eds., Neuroleptic Malignant Syndrome and Related Conditions, 2nd Edition, American Psychiatric Publishing, Washington, DC, 1-44.
[19]	Shalev, A., Hermesh, H. and Munitz, H. (1989) Mortality from Neuroleptic Malignant Syndrome. Journal of Clinical Psychiatry, 50, 18-25.
[20]	Reulbach, U., Dutsch, C., Biermann, T., Sperling, W., Thuerauf, N., Kornhuber, J. and Bleich, S. (2007) Managing an Effective Treatment for Neuroleptic Malignant Syndrome. Critical Care, 11, R4.
[21]	Rosebush, R.L., Stewart, T. and Mazurek, M.F. (1991) The Treatment of Neuroleptic Malignant Syndrome. Are Dantrolene and Bromocriptine Useful Adjuncts to Supportive Care? British Journal of Psychiatry, 159, 709-712. http://dx.doi.org/10.1192/bjp.159.5.709
[22]	Ginz, H.F., Levano, S., Girard, T., Urwyler, A. and Hamel, C. (2012) Dantrolene for Severe Rhabdomyolysis in Staphylococcus aureus Toxic Shock Syndrome. European Journal of Anaesthesiology, 29, 161-162. http://dx.doi.org/10.1097/EJA.0b013e32834c7c9d
[23]	Levenson, J.L. (1985) Neuroleptic Malignant Syndrome. American Journal of Psychiatry, 142, 1137-1145. http://dx.doi.org/10.1176/ajp.142.10.1137
[24]	ACCP/SCCM (1992) American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions of Sepsis and Organ Failure and Guidelines for the Use on Innovative Therapies in Sepsis. Critical Care Medicine, 20, 864-874. http://dx.doi.org/10.1097/00003246-199206000-00025
[25]	Sachdev, P.S. (2005) A Rating Scale for Neuroleptic Malignant Syndrome. Psychiatry Research, 135, 249-256. http://dx.doi.org/10.1016/j.psychres.2005.05.003
[26]	Nisijima, K. and Shioda, K. (2013) Temporal Changes in Serum Creatine Kinase Concentration and Degree of Muscle Rigidity in 24 Patients with Neuroleptic Malignant Syndrome. Neuropsychiatric Disease and Treatment, 9, 853-859. http://dx.doi.org/10.2147/NDT.S45084
[27]	Rosenberg, M.R. and Green, M. (1989) Neuroleptic Malignant Syndrome. Review of Response to Therapy. JAMA Internal Medicine, 149, 1927-1931. http://dx.doi.org/10.1001/archinte.1989.00390090009002
[28]	Sakkas, P., Davis, J.M., Janicak, P.G. and Wang, Z.Y. (1991) Drug Treatment of the Neuroleptic Malignant Syndrome. Psychopharmacology Bulletin, 27, 381-384.
[29]	Hollander, A.S., Olney, R.C., Blackett, P.R. and Marshall, B.A. (2003) Fatal Malignant Hyperthermia Like Syndrome with Rhabdomyolysis Complicating the Presentation of Diabetes Mellitus in Adolescent Males. Pediatrics, 111, 1447-1452. http://dx.doi.org/10.1542/peds.111.6.1447
[30]	Morales, A.E. and Rosenbloom, A.L. (2004) Death Caused by Hyperglycemic Hyperosmolar State at the Onset of Type 2 Diabetes. Journal of Pediatrics, 144, 270-273. http://dx.doi.org/10.1016/j.jpeds.2003.10.061
[31]	Carchman, R.M., Dechert-Zeger, M., Calikoglu, A.S. and Harris, B.D. (2005) A New Challenge in Pediatric Obesity: Pediatric Hyperglycemic Hyperosmolar Syndrome. Pediatric Critical Care Medicine, 6, 20-24. http://dx.doi.org/10.1097/01.PCC.0000149134.61673.77
[32]	Kilbane, B.J., Mehta, S., Backeljauw, P.F., Shanley, T.P. and Crimmins, N.A. (2006) Approach to Management of Malignant Hyperthermia-Like Syndrome in Pediatric Diabetes Mellitus. Pediatric Critical Care Medicine, 7, 169-173. http://dx.doi.org/10.1097/01.PCC.0000192340.09136.82
[33]	Hotchkiss, R.S. and Karl, I.E. (1994) Dantrolene Ameliorates the Metabolic Hallmarks of Sepsis in Rats and Improves Survival in a Mouse Model of Endotoxemia. Proceedings of the National Academy of Sciences of the United States of America, 91, 3039-3043. http://dx.doi.org/10.1073/pnas.91.8.3039